William Blair Growth Fund on Twist Bioscience Corp.
Thesis
Twist Bioscience's moat is its silicon-based miniaturized DNA manufacturing technology, which enables much greater scale than legacy methods. The company continues to show broad commercial momentum in DNA Synthesis and Protein Solutions and Next Generation Sequencing. AI-enabled drug discovery is a meaningful tailwind because pharmaceutical customers value Twist's speed, quality and cost, while margins are moving toward profitability targets. The fund trimmed the position but still believes the secular shift toward synthetic biology can support sustainable share gains.
“Twist’s value proposition of high-throughput, high quality and low-cost pricing is differentiated and should allow for sustainable share gains”